Target intelligence / Profile preview

Poliovirus type 1 antigen, Poliovirus type 2 antigen, Poliovirus type 3 antigen (None; abbreviated nomenclature (e.g., PV1 antigen) is sometimes used in laboratory contexts, but not widely standardized)

Target
None; abbreviated nomenclature (e.g., PV1 antigen) is sometimes used in laboratory contexts, but not widely standardized
Molecular classification
Other (viral capsid protein antigen), Serotype antigen
01

Overview

The **polio virus antigens** are immunogenic structures present on the non-enveloped, icosahedral capsid of poliovirus serotypes 1, 2, and 3[3][5]. Each serotype possesses unique antigenic determinants (epitopes) that are recognized by neutralizing antibodies; these determinants overlap or lie adjacent to the binding site for the host cellular receptor CD155[1][5]. Structural studies show the epitopes are located around the fivefold symmetry axis (“canyon”) of the capsid, differing subtly between serotypes[1][5]. These antigens are the basis for polio vaccines, which expose the immune system to type-specific capsid proteins, inducing long-lasting protection against poliovirus infection[3][1][4]. They are not human proteins or classic pharmaceutical targets; rather, they are crucial for immune recognition and vaccine-mediated immunity.

Other names
Poliovirus antigen type 1Poliovirus antigen type 2Poliovirus antigen type 3PV1 antigenPV2 antigenPV3 antigenPoliovirus capsid antigen (less common)
02

Mechanism of action

Induction of protective immune response through antibody binding, neutralization of viral particles, prevention of virus-receptor interaction

03

Biological functions

Immune response activation (elicitation of neutralizing antibodies)
04

Disease associations

Infection (poliomyelitis)
05

Safety considerations

None intrinsic to the antigen itself; concerns arise with vaccine formulations (e.g., OPV may rarely cause vaccine-derived poliovirus)
06

Interacting drugs

Poliovirus vaccine (Inactivated polio vaccine [IPV], Oral polio vaccine [OPV])

1 more in the full profile.

07

Biomarkers

Antibody titers against poliovirus type 1/2/3 antigens (used as biomarkers for vaccine response efficacy)

Beyond the preview

Go deeper on Poliovirus type 1 antigen, Poliovirus type 2 antigen, Poliovirus type 3 antigen (None; abbreviated nomenclature (e.g., PV1 antigen) is sometimes used in laboratory contexts, but not widely standardized).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus type 1 antigen, Poliovirus type 2 antigen, Poliovirus type 3 antigen (None; abbreviated nomenclature (e.g., PV1 antigen) is sometimes used in laboratory contexts, but not widely standardized).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call